Roquefort Therapeutics plc

Equities

ROQ

GB00BMDQ2T15

Investment Management & Fund Operators

Market Closed - London S.E. Other stock markets 09:05:15 03/06/2024 pm IST			5-day change	1st Jan Change
4.9 ^GBX	-2.00%		-6.67%	-32.41%

23/05	Windward wins deal; Kodal progresses at Bougouni	AN
23/05	Roquefort Therapeutics plc Announces Executive and Board Changes	CI

Roquefort Therapeutics demonstrates initial safety in two antibody programmes

January 26, 2023 at 01:37 pm IST

(via NewsDirect)

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald speaks to Proactive's Thomas Warner after announcing that the company's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programmes have successfully demonstrated safety in pre-clinical studies. Reginald says that he's now hoping to "move rapidly into efficacy testing".

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Roquefort Therapeutics plc

Windward wins deal; Kodal progresses at Bougouni	24/05	AN
Roquefort Therapeutics plc Announces Executive and Board Changes	23/05	CI
EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany	27/04	AN
Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35	26/04	MT
Roquefort Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Roquefort cancels fundraise after "unusual" stock movements	05/04	AN
Roquefort Therapeutics Shelves Potential Placing Following Unusual Price Movements	05/04	MT
Roquefort celebrates "significant milestones" in cancer research	11/03	AN
Roquefort Therapeutics plc Provides an Update on the Development of the Midkine Midkine mRNA and STAT-6 siRNA programs	11/03	CI
Roquefort hails further MK studies, licence talks continue	06/02	AN
Roquefort Therapeutics plc Provides an Update on Its Pre-Clinical Drug Development Programs	06/02	CI
Roquefort Therapeutics Announces Significant Mesodermal Killer Cell Milestone	06/11	CI
EARNINGS: Biome loss widens; Amicorp focused on growth post-IPO	27/23/27	AN
Roquefort Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Roquefort files patent application for mRNA and RNA therapies	14/23/14	AN
Roquefort Therapeutics Files International Patent for Anti-cancer Therapeutics	14/23/14	MT
Roquefort Therapeutics plc Announces the Successful Filing of the International Phase PCT Patent for Its Proprietary Anti-Cancer mRNA and RNA Oligonucleotide Therapeutics	14/23/14	CI
Roquefort announces new sirNA sequences and patent filing	07/23/07	AN
Roquefort Therapeutics Completes Development of Four Novel Small Interfering RNA Sequences; Shares Up 5%	07/23/07	MT
Anpario trading in line, Likewise Group sales rise	29/23/29	AN
Plant Health Care announces GBP2.8 million fundraise	23/23/23	AN
Roquefort Therapeutics Expects Q4 Closing for In Vivo Studies for Anti-Cancer Program	22/23/22	MT
Roquefort Therapeutics celebrates cancer antibody trial results	19/23/19	AN
Roquefort Therapeutics' Bone Cancer Antibodies Lower Tumor Growth Rate in Efficacy Trial	19/23/19	MT
Roquefort says anti-cancer mRNA study shows positive results	13/23/13	AN

Chart Roquefort Therapeutics plc

Duration

Period

More charts

Company Profile

Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.

Sector

Investment Management & Fund Operators

Calendar

25/10/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Investment Management & Fund Operators

	1st Jan change	Capi.
ROQUEFORT THERAPEUTICS PLC	-32.41%	82.16L
BLACKROCK, INC.	-4.52%	11TCr
UBS GROUP AG	+9.04%	10TCr
BROOKFIELD CORPORATION	+12.14%	6.74TCr
BANK OF NEW YORK MELLON CORPORATION (THE)	+14.21%	4.46TCr
AMERIPRISE FINANCIAL, INC.	+13.00%	4.34TCr
3I GROUP PLC	+20.86%	3.51TCr
T. ROWE PRICE GROUP INC.	+8.27%	2.63TCr
STATE STREET CORPORATION	-2.93%	2.28TCr
PRINCIPAL FINANCIAL GROUP, INC.	+2.47%	1.92TCr

Other Investment Management & Fund Operators